Rifaximin for Treatment of Bloating in Children and Adults With Cystic Fibrosis

NCT ID: NCT05408910

Last Updated: 2025-06-27

Basic Information

• Recruitment Status: WITHDRAWN
• Clinical Phase: PHASE2/PHASE3
• Study Classification: INTERVENTIONAL
• Study Start Date: 2025-07-31
• Study Completion Date: 2025-09-30

Brief Summary

Gastrointestinal symptoms are commonly reported in as much as 65% of people with CF even independent of pancreatic enzyme replacement therapy (PERT) and the most frequent of these symptoms are bloating/distension, flatulence, abdominal pain and bowel habit changes. An alteration in the intestinal microbiome due to intestinal dysmotility, inflammation or other changes including pH changes in the intestine related to CFTR gene mutation may cause intestinal dysbiosis leading to a bacterial overgrowth in the proximal small intestine which may explain some of the findings of distension and bloating in CF.

Our small pilot study aims to investigate use of the only FDA-approved antibiotic, rifaximin for a GI syndrome- IBS, to treat bloating and global GI symptoms in CF patients with bloating and distension. Our goal is to recruit patients >12 years and age/sex matched into rifaximin and placebo arms with total of 100 recruited subjects recruited.

Detailed Description

Gastrointestinal symptoms are commonly reported in persons with cystic fibrosis-both adults and pediatrics- and these symptoms cause distress, impact patients quality of life, and can lead to poor nutrition. One of the findings from our largest US study of patient-reported GI symptom outcomes in CF called GALAXY, which enrolled 402 adults and children with CF, was the finding of high rates of patient dissatisfaction with current GI treatments as well as commonly reported symptoms of bloating (48%), fullness (67%) with meals and abdominal distension (50%). This study aims to evaluate if this same-nonsystemically absorbed and noninvasive antibiotic can be used to treat similar commonly reported symptoms in people with CF.

Conditions

Cystic Fibrosis; Abdominal Pain; Small Bowel Disease

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: TRIPLE

Study Groups

Treatment

Participants in this arm will receive Rifaximin 550 mg three times daily for 14 days.

Group Type: EXPERIMENTAL

Rifaximin 550 MG Oral Tablet [XIFAXAN]

Intervention Type: DRUG

Participants in this arm will receive Rifaximin 550 mg three times daily for 14 days.

Placebo

Participants in this arm will receive placebo three times daily for 14 days.

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

Participants in this arm will receive placebo three times daily for 14 days.

Interventions

Rifaximin 550 MG Oral Tablet [XIFAXAN]

Participants in this arm will receive Rifaximin 550 mg three times daily for 14 days.

Intervention Type: DRUG

Placebo

Participants in this arm will receive placebo three times daily for 14 days.

Intervention Type: DRUG

Other Intervention Names

XIFAXAN

Eligibility Criteria

Inclusion Criteria

1. Confirmed CF diagnosis who are enrolled in the CFF registry.

2. Mild to severe symptom severity defined as abdominal Distention score ≥ 2 and/or bloating score ≥ 2 on a Likert Scale of 0-6)

3. Patient age ≥12 years and ≥ 30 kilograms (~66.15 lbs)

4. Ability to provide informed consent or presence of legally authorized representative (LAR)

5. Ability to take drug or placebo by mouth (Pill must be intact. May not be opened, crushed, or modified to aid in ingestion)

Exclusion Criteria

1. Subjects who have previously been allergic to rifaximin or had a hypersensitivity to rifamycin or used rifaximin for any reason within three months (12 weeks) of the study start date

2. Subjects with FEV1 < 40 (as measured within the last 12 months) will be excluded from the study given potential risks in subjects with advanced lung disease

3. Subjects who have received a new antibiotic for treatment of an acute pulmonary infection, or antibiotics for any other infection within 4 weeks prior to randomization or during the study period. Cyclic Antibiotics- Inhaled cyclic antibiotics are allowed at any timepoint. Oral or systemic cyclic antibiotics are exclusionary except for prophylactic antibiotics (e.g., azithromycin) which are allowed. New prophylactic antibiotics cannot be started within 4 weeks of randomization.

4. Subjects with a recent pulmonary exacerbation defined as 4 weeks prior to screening will not be enrolled

5. Subjects who are on probiotics will be asked to discontinue the use of probiotics 14 days prior to randomization as probiotics can alter the gut microbiome and cause bloating

6. Subjects with newly initiated cystic fibrosis transmembrane conductance regulator (CFTR) modulator treatments within one month prior to the study

7. Subjects with new onset of distal intestinal obstruction syndrome (DIOS) or constipation

8. Subjects with advanced liver disease defined by:

• portal hypertension and/or child Pugh B or C cirrhosis
• or those with elevated liver enzymes-both AST/ALT > 3 times the upper limit of normal at screening

9. Subjects with bilirubin or alkaline phosphatase elevations > 2 times the upper limit of normal at screening will be excluded as this may be related to CFTR modulator use

10. Women of childbearing potential who are pregnant, trying to become pregnant, breastfeeding, or not using an acceptable method of contraception as described in Section 6.2.

11. Known clostridium difficile colitis. Colonization with c. difficile is not exclusionary.

• Minimum Eligible Age: 12 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Nationwide Children's Hospital

OTHER

Sponsor Role: collaborator

University of Minnesota

OTHER

Sponsor Role: collaborator

University of Texas Southwestern Medical Center

OTHER

Sponsor Role: collaborator

Wake Forest University Health Sciences

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Baha Moshiree, MD

Role: PRINCIPAL_INVESTIGATOR

Wake Forest University Health Sciences

References

Furnari M, De Alessandri A, Cresta F, Haupt M, Bassi M, Calvi A, Haupt R, Bodini G, Ahmed I, Bagnasco F, Giannini EG, Casciaro R. The role of small intestinal bacterial overgrowth in cystic fibrosis: a randomized case-controlled clinical trial with rifaximin. J Gastroenterol. 2019 Mar;54(3):261-270. doi: 10.1007/s00535-018-1509-4. Epub 2018 Sep 19.

Reference Type: BACKGROUND

PMID: 30232597 (View on PubMed)

Other Identifiers

MOSHIR21-A0-I

Identifier Type: OTHER

Identifier Source: secondary_id

IRB00086338

Identifier Type: -

Identifier Source: org_study_id